Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 20Colonic Neoplasms 20Carcinoma, Renal Cell 17Fallopian Tube Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Brain Neoplasms 10Neoplasms 9Glioblastoma 9Brenner Tumor 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Oligodendroglioma 6Gliosarcoma 6Glioma 6Breast Neoplasms, Male 6Adenocarcinoma of Lung 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Astrocytoma 5Adenocarcinoma, Bronchiolo-Alveolar 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

Amifostine 9Radiotherapy 6Cisplatin 5Paclitaxel 4Etoposide 3Cyclophosphamide 3Carboplatin 3sargramostim 1lometrexol 1denileukin diftitox 1Thiotepa 1Taxes 1Silymarin 1Radiation 1Pyridostigmine Bromide 1Phenobarbital 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Irinotecan 1Ifosfamide 1Idarubicin 1Folic Acid 1Filgrastim 1Fibroblast Growth Factor 7 1Docetaxel 1Dexamethasone 1Cytarabine 1Cyclosporine 1Bleomycin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Drug-Related Side Effects and Adverse Reactions × Bevacizumab × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡